Curcumin Can Decrease Tissue Inflammation and the Severity of HSV-2 Infection in the Female Reproductive Mucosa.

Area of Science:

• Immunology
• Virology
• Nanotechnology

Background:

• Herpes Simplex Virus Type 2 (HSV-2) is a prevalent sexually transmitted infection and a risk factor for HIV acquisition.
• Curcumin has demonstrated anti-HSV-2 and anti-inflammatory properties in vitro.
• Effective in vivo delivery of curcumin for genital tract infections remains a challenge.

Purpose of the Study:

• To investigate the efficacy of nanoparticle-encapsulated curcumin delivered via various routes in reducing inflammation and HSV-2 infection in the female genital tract (FGT).
• To evaluate the anti-inflammatory and anti-viral activities of curcumin nanoparticles in a mouse model.

Main Methods:

• Female mice were pre-treated with curcumin nanoparticles (oral, intraperitoneal, intravaginal) and exposed to CpG-oligodeoxynucleotide (ODN) or HSV-2 intravaginally.
• Inflammatory histopathology, cytokine (IL-6, TNF-α, MCP-1) production, and viral pathology were assessed.
• Alternative formulations of crude curcumin and solid dispersions were tested for anti-viral effects.

Main Results:

• Intravaginal delivery of curcumin nanoparticles significantly reduced CpG-ODN-induced inflammation and pro-inflammatory cytokine production in the FGT.
• Oral or intraperitoneal delivery of curcumin nanoparticles did not yield similar anti-inflammatory effects.
• Curcumin nanoparticles did not prevent HSV-2 infection or reduce pathology. However, crude curcumin and solid dispersions improved survival and delayed pathology post-HSV-2 infection.

Conclusions:

• Intravaginal delivery of curcumin nanoparticles effectively reduces local inflammation in the female genital tract.
• Curcumin's anti-inflammatory properties may mitigate HSV-2 severity and potentially reduce HIV acquisition risk.
• Further research into curcumin formulations is needed to establish anti-viral efficacy in vivo.